CRISPR Therapeutics AG (CRSP)
115.32 -0.17 (-0.15%)
After hours: 6:03PM EST
Chart Events
Performance Outlook
| Previous Close | 119.08 |
| Open | 117.54 |
| Bid | 114.19 x 900 |
| Ask | 115.50 x 800 |
| Day's Range | 109.55 - 122.39 |
| 52 Week Range | 32.30 - 220.20 |
| Volume | 3,603,306 |
| Avg. Volume | 2,414,983 |
| Market Cap | 8.711B |
| Beta (5Y Monthly) | 2.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.29 |
| Earnings Date | Apr 26, 2021 - Apr 30, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 157.40 |
Fair Value
Related Research
- Motley Fool
Is CRISPR Stock Heading to $160 in 2021?
One analyst thinks the company's foundational gene-editing tools have far more potential than many realize.
- GlobeNewswire
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March: Barclays Global Healthcare ConferenceDate: Tuesday, March 9, 2021Time: 10:20 a.m. ET 33rd Annual Roth ConferenceDate: Monday, March 15, 2021Time: 1:30 p.m. ET A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners. Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com Media Contact:Rachel Eides WCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com
- Motley Fool
Why It's Time to Go All-In on These 3 Revolutionary Stocks
Virgin Galatic Holdings (NYSE: SPCE), CRISPR Therapeutics (NASDAQ: CRSP), and Churchill Capital Corp IV (NYSE: CCIV) are three stocks that have returned between 56% and 193% over the past 12 months alone. Today, let's look at why a commercial space travel company, a gene therapy biotech, and an electric vehicle (EV) manufacturer are among the most revolutionary stocks to buy now. With no sales, more than $273 million in net losses, and a market cap of $8.7 billion, billionaire Richard Branson's space leisure company, Virgin Galactic, may be a surprising addition to this list.
